- You can view the full Novo Nordisk A/S Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.
Shares in the stock decline only marginally as the pharmaceuticals group sticks with its full-year forecast.
Novo Nordisk (NVO) is developing new types of insulin, such as a pill-based form, in response to growing competitive pressures.